Helicobacter pylori H. pylori Diagnostics Market Is Set to Experience Revolutionary Growth by 2030

The Helicobacter pylori (H. pylori) diagnostics Market was valued at USD 554.46 million in 2021. It is expected to increase from USD 587.68 million in 2022 to USD 953.25 million by 2030, with a compound annual growth rate (CAGR) of 6.01% during the forecast period of 2023-2030.The popularity of H. pylori diagnostics is growing due to its benefits in improving diagnosis, enabling effective treatment, and reducing healthcare costs.

Detecting H. pylori infections early through diagnostic tests plays a crucial role in preventing disease progression and reducing complications. These tests accurately identify the presence of the bacteria in a patient's stomach or intestines, allowing healthcare providers to initiate appropriate treatment promptly. Early treatment leads to better patient outcomes by reducing symptoms and promoting faster healing of ulcers. Additionally, early detection can prevent the development of severe complications, such as stomach cancer. The H. pylori diagnostic market provides various non-invasive tests, including blood tests, breath tests, and stool antigen tests, which are comfortable for patients and easily accessible. Moreover, these tests are cost-effective, making them available to a larger population.

Request Free Sample Report @ https://www.marketdigits.com/request/sample/646

Helicobacter pylori H. pylori Diagnostics Market Top Player's Company Profiles

• Abbott Laboratories
• Allergan plc
• AstraZeneca plc
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Halyard Health, Inc.
• Hologic, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Pfizer, Inc.
• Quidel Corporation
• Sanofi S.A.
• Seegene Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.
• Trinity Biotech plc
• ZEUS Scientific, Inc.
• Helicobacter pylori H. pylori Diagnostics Market

Helicobacter pylori H. pylori Diagnostics Market Analysis by End-User

The largest market share in the Helicobacter pylori (H. pylori) diagnostics market is held by the hospitals segment, driven by several factors. These include the easy identification of diseases, the presence of doctors, and the increasing prevalence of conditions such as gastric ulcers, gastritis, stomach cancer, duodenal ulcers, and small intestine infections.

During the forecast period, the diagnostic laboratories segment is expected to exhibit the highest compound annual growth rate (CAGR). This growth can be attributed to the growing awareness of infectious diseases and the availability of more specialized and efficient methods for detecting infections. In terms of revenue, the hospitals and diagnostic laboratories segments collectively accounted for over 80% of the market share during the projected period.

In terms of regional insights, North America dominates the Helicobacter pylori H. pylori diagnostics market, driven by factors such as high healthcare expenditure, favorable reimbursement policies, and a significant patient population. However, the Asia Pacific region is expected to emerge as the fastest-growing market in the near future. This growth can be attributed to factors such as the increasing prevalence of infections, expanding healthcare infrastructure, and rising demand for advanced treatments. The large population base in the Asia Pacific region also presents significant opportunities for market growth in the coming years.

Request For Discount @ https://www.marketdigits.com/request/discount/646

Recent Developments

In March 2023, RedHill, a specialty biopharmaceutical company, made an announcement regarding the complete repayment of all its debt obligations. This includes the repayment of principal, interest, revenue interest, prepayment premiums, and exit fees. The Credit Agreement between RedHill's U.S. subsidiary, RedHill Biopharma Inc., and HCR has been fully settled.

Key market trends in the global Helicobacter pylori (H. pylori) diagnostics market indicate a growing demand for non-invasive diagnostic tests such as serology tests and urea breath tests. These tests are gaining popularity due to their minimal invasiveness and user-friendly nature. As a result, there is a significant increase in the overall demand for these non-invasive diagnostic tests.

Enquire about the report @ https://www.marketdigits.com/request/enquiry-before-buying/646

Contact US:
1248 CarMia Way Richmond,
VA 23235, United States.
Phone: +1 510-730-3200
Email: mailto:sales@marketdigits.com
Website: https://www.marketdigits.com

About MarketDigits:
MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

This release was published on openPR.